Last reviewed · How we verify
NCT03023904
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Phase 2 trial testing Nivolumab in Recurrent Non-Small Cell Lung Carcinoma. Withdrawn.
30 July 2019
Quick facts
| Lead sponsor | Vanderbilt-Ingram Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 29 December 2017 |
| Primary completion | 30 July 2019 |
| Estimated completion | 30 July 2020 |
Drugs / interventions tested
- Nivolumab (nivolumab) — full drug profile →
- Laboratory Biomarker Analysis — full drug profile →
Conditions studied
- Recurrent Non-Small Cell Lung Carcinoma — all drugs for Recurrent Non-Small Cell Lung Carcinoma →
- Stage IV Non-Small Cell Lung Cancer — all drugs for Stage IV Non-Small Cell Lung Cancer →
Sponsor
Vanderbilt-Ingram Cancer Center — full company profile →
Who can join
18 and older, any sex, with Recurrent Non-Small Cell Lung Carcinoma or Stage IV Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well nivolumab works in treating patients with stage IV lung cancer or that has come back after initial treatment who has high mutation loads. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of
Chinese Lung Cancer Immunotherapy].
Liu J, Zhang S, Li S, Cheng Y. · · 2017 · cited 1× · PMID 29061217 · DOI 10.3779/j.issn.1009-3419.2017.10.06
Verify or expand the search:
- PubMed search for NCT03023904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nivolumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
- NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
Other recruiting trials for Recurrent Non-Small Cell Lung Carcinoma
Currently open trials in the same condition.
- NCT02495896 — Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastati · Phase 1 · active not recruiting
- NCT02438722 — S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGF · Phase 2, PHASE3 · active not recruiting
Other Vanderbilt-Ingram Cancer Center trials
Trials by the same sponsor.
- NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
- NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
- NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
- NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03023904 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
- Last refreshed: 25 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03023904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing